Research programme: histone deacetylase inhibitors - BioMarin

Drug Profile

Research programme: histone deacetylase inhibitors - BioMarin

Alternative Names: HDAC inhibitors - BioMarin

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Repligen Corporation
  • Developer BioMarin Pharmaceutical; Repligen Corporation
  • Class Small molecules
  • Mechanism of Action Histone deacetylase inhibitors; Transcription factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Friedreich's ataxia; Huntington's disease
  • Discontinued Cognition disorders; Spinal muscular atrophy

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Friedreich's ataxia in USA (PO)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Huntington's-disease in USA (PO)
  • 21 Jan 2014 BioMarin enters into a license agreement with Repligen to purchase histone deacetylase inhibitor (HDACi) library and related intellectual property
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top